Medical Policies and Clinical Utilization Management Guidelines Update
Please note, this communication applies to Healthy Blue + Medicare℠ (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).
The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. Please note: The Medical Policies and Clinical UM Guidelines below are followed in the absence of Medicare guidance.
Please share this notice with other members of your practice and office staff.
To view a guideline, visit https://medpol.providers.amerigroup.com/green-provider/medical-policies-and-clinical-guidelines-full-list.
Notes/Updates:
Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
- *CG-LAB-15 – Red Blood Cell Folic Acid Testing
- RBC folic acid testing is considered not medically necessary in all cases
- *CG-LAB-16 – Serum Amylase Testing
- Serum amylase testing is considered not medically necessary for acute and chronic pancreatitis and all other conditions
- *CG-GENE-04 – Molecular Marker Evaluation of Thyroid Nodules
- Added the Afirma Xpression Atlas as not medically necessary
- SURG.00158 – Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain
- A new Medical Policy was created from content contained in DME.00011
- There are no changes to the policy content.
- Publish date is December 16, 2020.
- CG-GENE-21 – Cell-Free Fetal DNA-Based Prenatal Testing
- A new Clinical Guideline was created from content contained in GENE.00026
- There are no changes to the guideline content.
- Publish date is December 16, 2020.
Medical Policies
On November 5, 2020, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Blue Cross NC. These guidelines take effect June 8, 2021.
PUBLISH DATE | MEDICAL POLICY NUMBER | MEDICAL POLICY TITLE | NEW OR REVISED |
---|---|---|---|
11/12/2020 | ANC.00009 | Cosmetic and Reconstructive Services of the Trunk and Groin | Revised |
11/12/2020 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | Revised |
11/12/2020 | MED.00129 | Gene Therapy for Spinal Muscular Atrophy | Revised |
12/16/2020 | SURG.00011 | Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft Tissue Grafting | Revised |
Clinical UM Guidelines
On November 5, 2020, the MPTAC approved the following Clinical UM Guidelines applicable to Blue Cross NC. These guidelines adopted by the medical operations committee for Blue Cross NC members on November 19, 2020. These guidelines take effect June 8, 2021.
PUBLISH DATE | CLINICAL UM GUIDELINE NUMBER | CLINICAL UM GUIDELINE TITLE | NEW OR REVISED |
---|---|---|---|
12/16/2020 | *CG-LAB-15 | Red Blood Cell Folic Acid Testing | New |
12/16/2020 | *CG-LAB-16 | Serum Amylase Testing | New |
11/12/2020 | CG-DME-42 | Non-implantable Insulin Infusion and Blood Glucose Monitoring Devices | Revised |
12/16/2020 | *CG-GENE-04 | Molecular Marker Evaluation of Thyroid Nodules | Revised |
12/16/2020 | CG-GENE-18 | Genetic Testing for TP53 Mutations | Revised |
12/16/2020 | CG-GENE-20 | Epidermal Growth Factor Receptor (EGFR) Testing | Revised |
11/12/2020 | CG-MED-87 | Single Photon Emission Computed Tomography Scans for Noncardiovascular Indications | Revised |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.